Send the following on WhatsApp
Continue to ChatBoehringer Ingelheim’s BI 690517 shows up to 39.5% albuminuria reduction in Phase II trial https://business-news-today.com/boehringer-ingelheims-bi-690517-shows-up-to-39-5-albuminuria-reduction-in-phase-ii-trial/